Skip to content

Vaxess Technologies

2 viewers · 30d

Total raised

$73.6M

+$57.3M this year

3 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $57.3M
ROUNDS
3
INVESTORS
3
FOUNDED
N/A
HQ
Cambridge, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Vaxess Technologies, Inc. is a pioneering life sciences company focused on the development of innovative vaccine and therapeutic delivery technologies. Their flagship product, the MIMIX™ platform, is a cutting-edge transdermal patch system that aims to make vaccines and therapeutics more effective and accessible, particularly in challenging environments.

What sets it apart

Vaxess sets itself apart through its needle-free delivery method and its ability to eliminate the need for cold storage, which is crucial for vaccine distribution in resource-limited settings.

Funding history

3 rounds
Equity+1Mar 4, 2026
Form D
+$57.3M$73.6M total
Debt+1Aug 27, 2025
Form D
+$7.9M$16.3M total
Debt+1Feb 14, 2025
Form D
+$8.4M$8.4M total

Products

1 tracked

MIMIX™ Platform

Transdermal Delivery

The MIMIX™ platform is an innovative transdermal patch delivery system that utilizes dissolvable microarray technology to administer vaccines and therapeutics painlessly. Each patch is composed of microarray tips made from silk fibroin proteins, which dissolve upon application to the skin, ensuring a controlled and sustained release of the active ingredients over time to enhance immune responses.

  • Needle-free application for user comfort
  • Eliminates refrigeration requirements for easier logistics
  • Controlled release mimics natural infection for enhanced effectiveness

Links

WebsiteSEC EDGAR filings